RNA-based precision medicine in glioblastoma driven by oncogenic gene fusions
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201213
DOI: 10.1016/j.omton.2026.201213 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Maël Bouillon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Université D'Angers, INSERM, CNRS, CRCINA, 49000 Angers, France. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conseil Régional des Pays de la Loire, Universite Angers, Institut National de la Santé et de la Recherche Médicale.
Abstract (Originalsprache)
Glioblastoma, the most common primary central nervous system tumor, is the leading cause of death in neuro-oncology. Gene fusions, caused by chromosomal rearrangements, may act as drivers of tumorigenesis in glioblastoma. These fusions result from the juxtaposition of two genes, leading to the production of a chimeric protein and, in most cases, constitutive activation of a tyrosine kinase receptor. Despite the use of tyrosine kinase inhibitors to block the oncogenic activity of gene fusions, clinical responses in glioblastoma remain poor compared to those in other cancers, highlighting the need for innovative therapeutic strategies. RNA interference, using small interfering RNAs or micro-RNAs, offers a promising approach to target these oncogenic fusions. Through specific silencing, small interfering RNAs spare healthy cells, avoiding the adverse effects associated with tyrosine kinase inhibitors. Recent advances in biotechnology (e.g., antisense oligonucleotides and aptamers) and delivery systems have improved small interfering RNA stability, specificity, and ability to cross the blood-brain barrier. This review discusses these advances and their potential applications to target oncogenic gene fusions in glioblastoma. RNA interference-based therapy represents a critical area of research that could improve the survival of patients with glioblastoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Université D'Angers, INSERM, CNRS, CRCINA, 49000 Angers, France.
- Department of Pathology, CHU Angers, Angers, France.
- Institut Pasteur, Department of Structural Biology and Chemistry, Laboratory for Bioorganic Chemistry of Nucleic Acids, CNRS UMR3523, 28 Rue Du Docteur Roux, 75724 Paris, France.
Förderung
- Conseil Régional des Pays de la Loire
- Universite Angers
- Institut National de la Santé et de la Recherche Médicale
- National League Against Cancer
- Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation
- Ministère de l'Enseignement supérieur et de la Recherche
- Agence Nationale de la Recherche
Zitieren
APA
Bouillon, M., Lapoujade, C., Basset, L., Fontaine, A., Hollenstein, M., Garcion, E., & Rousseau, A. (2026). RNA-based precision medicine in glioblastoma driven by oncogenic gene fusions. Molecular Therapy Oncology, 34(2), 201213. https://doi.org/10.1016/j.omton.2026.201213
Vancouver
Bouillon M, Lapoujade C, Basset L, Fontaine A, Hollenstein M, Garcion E, et al. RNA-based precision medicine in glioblastoma driven by oncogenic gene fusions. Molecular Therapy Oncology. 2026;34(2):201213. doi:10.1016/j.omton.2026.201213
BibTeX
@article{Bouillon2026,
author = {Bouillon, Maël and Lapoujade, Clémentine and Basset, Laëtitia and Fontaine, Alix and Hollenstein, Marcel and Garcion, Emmanuel and Rousseau, Audrey},
title = {RNA-based precision medicine in glioblastoma driven by oncogenic gene fusions},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201213},
doi = {10.1016/j.omton.2026.201213}
}
EUVIMED